A Phase 1/2 interventional study of AZD7760 and Placebo in Staphylococcus Aureus, sponsored by AstraZeneca. Active, not recruiting at 40 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by AstraZeneca · Phase 1/2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 125 studies in Staphylococcal Infections with a site in United States — 6 open to participants now, 11 under way, none of them phase 3. Staphylococcal Infections · United States.
Among the 125 studies in Staphylococcal Infections with a site in United States, this one is the 33rd largest by enrollment of the 92 interventional ones that give a count, is one of 5 that started in 2024, is one of 6 in phase 1/2, reaches primary completion later than 6 of the 10 other live ones, and was the 124th registered.
304 studies on the registry are indexed under Staphylococcal Infections; 35 are open to participants now.
Browse Staphylococcal Infections studies →6 of the 125 studies in Staphylococcal Infections with a site in United States are open now. Recruiting first, the newest first:
National Institute of Allergy and Infectious Diseases (NIAID) · Sites in United States
Ages 2–120
Johns Hopkins University · Sites in United States
Ages 0–60 · Healthy volunteers
University of Virginia · Sites in United States
Ages 18–65
University of Melbourne · Sites in United States, Australia, Canada and 10 more countries
Texas Woman's University · Sites in United States
Ages 18–45 · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 22 Staphylococcal Infections studies recruiting now, 16 (73%) set no upper age limit and 4 (18%) stop at 75 or younger; 5 take children under 18; 5 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
125 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 26 · Phase 3 15 · Phase 4 16
First in 2000; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 242 is above the median of 124 across 198 interventional studies indexed under Staphylococcal Infections.
Median enrollment 158 across the 92 interventional studies, 217 across the 32 observational. Of the 105 that completed or were terminated, 44 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 125 have an industry lead sponsor. The 10 most frequent:
AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.
Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.
AstraZeneca has 2 studies filed under Staphylococcal Infections — fewer than ten, so there is no comparison to draw.
3 of the studies in Staphylococcal Infections with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06749457AstraZenecaA Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa) | 2027-03-08 |
| NCT01879761University of ChicagoImmune Resolution After Staphylococcus Aureus Bacteremia | 2027-06 |
| NCT06805994Johns Hopkins UniversityAdministering NMT to Reestablish Infant Nasal Microbiome Diversity Following Intranasal Mupirocin Treatment | 2027-09-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 125 studies in Staphylococcal Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa).
In the Phase I portion of the study, participants will be randomized to receive one of 3 dosages of AZD7760 or placebo as a single intravenous infusion.
Study details include:
In the Phase IIa portion of the study, participants will be randomized to receive either AZD7760 or placebo as 2 intravenous infusions given 3 months apart.
Study details include:
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Phase I:
Phase IIa:
Participants who meet all of the following disease status requirements:
Exclusion Criteria:
Phase I:
Phase IIa:
Regarding arteriovenous fistula (AVF) or arteriovenous graft (AVG):
(a) Future AVG or AVG: (i) Participants with central venous catheters currently in use for dialysis, and future plans for AVF or AVG use within 90 days of randomization are not eligible.
(ii) Participants with central venous catheters currently in use for dialysis, and future plans for AVF or AVG placement, but no plans for AVF or AVG use within 90 days of randomization are eligible.
(b) Existing AVG or AVG: (i) Participants with central venous catheters in use for dialysis, but also with an existing AVF or AVG that is not in use and with no future plans for use are eligible.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive a single dose of AZD7760 Dose A intravenously on Day 1.
Drug: AZD7760
Participants will receive a single dose of AZD7760 Dose B intravenously on Day 1.
Drug: AZD7760
Participants will receive a single dose of AZD7760 Dose C intravenously on Day 1.
Drug: AZD7760
Participants will receive a single dose of placebo on Day 1.
Other: Placebo
Participants will receive AZD7760 Dose D and placebo on Day 1 on Day 91.
Drug: AZD7760 · Other: Placebo
Participants will receive AZD7760 Dose E on Day 1 and Day 91.
Drug: AZD7760
Participants will receive placebo on Day 1 and on Day 91.
Other: Placebo
Participants will receive AZD7760 as a single intravenous infusion.
Participants will be administered placebo through intravenous infusion.
Phase I: Occurence of adverse events (AEs)
To evaluate the safety of AZD7760 administered as a single intravenous (IV) Dose A, B, or C.
Time frame: Day 1 to Day 181
Phase I: Occurence of medically-attended adverse events (MAAEs), serious adverse events (SAEs), and adverse events of special interest (AESIs)
To evaluate the safety of AZD7760 administered as a single IV Dose A, B, or C.
Time frame: Day 1 to Day 361
Phase IIa: Occurrence of AEs, MAAEs, SAEs, and AESIs
To evaluate the safety of AZD7760 compared with placebo as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E
Time frame: Day 1 to Day 181
Phase I: Maximum observed plasma (peak) drug concentration (Cmax)
To characterize the pharmacokinetics (PK) of AZD7760 in serum.
Time frame: Day 1 to Day 361
Phase I: Time to reach peak or maximum observed concentration following drug administration (tmax)
To characterize the PK of AZD7760 in serum.
Time frame: Day 1 to Day 361
Phase I: Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t1/2λz)
To characterize the PK of AZD7760 in serum.
Time frame: Day 1 to Day 361
Phase I: Area under the plasma concentration-curve from zero to the last quantifiable concentration (AUClast)
To characterize the PK of AZD7760 in serum.
Time frame: Day 1 to Day 361
Phase I: Area under plasma concentration-time curve from zero extrapolated to infinity (AUCinf)
To characterize the PK of AZD7760 in serum.
Time frame: Day 1 to Day 361
Phase I: Apparent volume of distribution at steady state (Vss)
To characterize the PK of AZD7760 in serum.
Time frame: Day 1 to Day 361
Phase I: Apparent volume of distribution at the terminal phase (Vz)
To characterize the PK of AZD7760 in serum.
Time frame: Day 1 to Day 361
Phase I: Incidence of ADA
To evaluate ADA responses to AZD7760 in serum.
Time frame: Day 1 to Day 361
Phase IIa: Cmax
To characterize the serum PK profiles of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E
Time frame: Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: tmax
To characterize the serum PK profiles of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E
Time frame: Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: t1/2λz
To characterize the serum PK profiles of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E
Time frame: Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: AUClast
To characterize the serum PK profiles of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E
Time frame: Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: AUCinf
To characterize the serum PK profiles of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E
Time frame: Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: Vss
To characterize the serum PK profiles of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E
Time frame: Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: Vz
To characterize the serum PK profiles of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E
Time frame: Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: Incidence of anti-drug antibodies (ADAs) to AZD7760 in serum
To evaluate ADA responses to AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E
Time frame: Day 1 to Day 181 and Day 1 to Day 451
Phase IIa: Occurrence of AEs
To evaluate the safety to Day 181 of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E
Time frame: Day 1 to Day 181
Phase IIa: Occurrence of MAAEs, SAEs, and AESIs
To evaluate the safety to Day 451 of AZD7760 administered as: * A single IV dose (at Day 1) of Dose D followed by placebo (at Day 91) * 2 IV doses (at Day 1 and Day 91) of Dose E
Time frame: Day 1 to Day 451
Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
Supporting information: Study protocol, Statistical analysis plan
Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Access criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Mar 2027, 26 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 6, 2026: primary completion Apr 2027 → Mar 2027 and completion Jan 2028 → Dec 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.